Overview
REGN market data
Price History
REGN price chart
Valuation & Profitability
- P/E (TTM)
- 16.48 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $41.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 54.1% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $541.00 – $821.11 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $72.9K · P/B 2.60 · P/S 4.89.
Company News
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - HBSSGlobenewswire Inc · Jul 24, 2026, 7:15 PM
Sanofi Drops Dupixent Successor Candidate After Assessing DataBenzinga · Jul 24, 2026, 6:10 PM
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000Benzinga · Jul 21, 2026, 1:51 PM
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline ProgressGlobenewswire Inc · Jul 21, 2026, 11:00 AM
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your PortfolioBenzinga · Jul 20, 2026, 9:11 PM
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various IndexesGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobenewswire Inc · Jul 15, 2026, 3:15 PM
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $854Benzinga · Jul 9, 2026, 3:40 PM
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $730Benzinga · Jul 8, 2026, 5:20 PM
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $696Benzinga · Jul 7, 2026, 3:50 PM